New England Journal of Medicine

The New England Journal of Medicine (NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It describes itself as the oldest continuously published medical journal in the world. The journal publishes editorials, papers on original research, review articles, correspondence, and case reports, and has a special section called "Images in Clinical Medicine". In September 1811, John Collins Warren, a Boston physician, along with James Jackson, submitted a formal prospectus to establish the New England Journal of Medicine and Surgery and Collateral Branches of Science as a medical and philosophical journal. Subsequently, the first issue of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science was published in January 1812. The journal was published quarterly. On April 29, 1823, another publication, the Boston Medical Intelligencer, appeared under the stewardship of Jerome V.C. Smith. The Intelligencer ran into financial troubles in the spring of 1827, and the editors of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science purchased it in February 1828

Publisher
Massachusetts Medical Society
Country
United States
History
The New England Journal of Medicine and Surgery (1812–1826);
The New England Medical Review and Journal (1827);
The Boston Medical and Surgical Journal (1828–1927);
The New England Journal of Medicine (1928–present)
Impact factor
53.484 (2010)

Some content from Wikipedia, licensed under CC BY-SA

Genetics

Genomic collision may explain why many kidney transplants fail

A genomic collision could explain why many kidney transplants fail, even when donors and recipients are thought to be well-matched, according to a new study from researchers at Columbia University Vagelos College of Physicians ...

Medications

Dabigatran doesn't beat aspirin for preventing recurrent stroke

(HealthDay)—Dabigatran is not superior to aspirin for preventing recurrent stroke in patients with recent history of embolic stroke of undetermined source, according to a study published in the May 16 issue of the New England ...

Neuroscience

AAN: Oral BTK inhibitor superior to placebo in multiple sclerosis

(HealthDay)—The selective Bruton's tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, ...

page 1 from 50